Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
The University of Pittsburgh will offer a unique Master of Science in Pharmacy Business Administration program through its pharmacy and graduate business schools.
Daniel Kraft, MD, chair of medicine at Singularity University and chair/founder of Exponential Medicine, discusses the technologies that will affect pharmacies most in the future.
Anne Burns RPh Vice President of Professional Affairs at the American Pharmacists Association talks how the pharmacist's role has evolved.
A virtual clinic launched by 1-800-Pharmacy and the Independent Pharmacy Cooperative aims to assist pharmacists at independent community pharmacies.
Latest Issues
$auto_registration$